Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.

ABSTRACT:

Background

Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report the dynamic variation characteristics and specificities of the gut microbiome during anti-PD-1 immunotherapy in HCC using metagenomic sequencing.

Results

Fecal samples from patients responding to immunotherapy showed higher taxa richness and more gene counts than those of non-responders. For dynamic analysis during anti-PD-1 immunotherapy, the dissimilarity of beta diversity became prominent across patients as early as Week 6. In non-responders, Proteobacteria increased from Week 3,

SUBMITTER: Zheng Y 

PROVIDER: S-EPMC6651993 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature